Carregando...
An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease
BACKGROUND: Bosentan has been shown to be a safe and efficacious treatment for idiopathic pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease. However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CH...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Pulsus Group Inc
2006
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2683328/ https://ncbi.nlm.nih.gov/pubmed/17149459 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|